Gary Lichtenstein

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREATâ„¢ registry
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 107:1409-22. 2012
  2. pmc A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Gastroenterol 107:1051-63. 2012
  3. ncbi request reprint Review article: Bowel preparation for colonoscopy--the importance of adequate hydration
    G R Lichtenstein
    Hospital of the University of Pennsylvania, Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Aliment Pharmacol Ther 26:633-41. 2007
  4. ncbi request reprint Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease
    Mark T Osterman
    Gary R Lichtenstein, MD Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Division of Gastroenterology, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Curr Treat Options Gastroenterol 10:195-207. 2007
  5. ncbi request reprint Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis
    Gary R Lichtenstein
    Center for Inflammatory Bowel Disease, University of Pennsylvania Health System, Philadelphia, PA, USA
    J Clin Gastroenterol 40:669-77. 2006
  6. ncbi request reprint Prevention and treatment of osteoporosis in inflammatory bowel disease
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia, PA 19104 4283, USA
    Inflamm Bowel Dis 12:797-813. 2006
  7. ncbi request reprint Safety of biologics in inflammatory bowel disease
    Wojciech Blonski
    Center for Inflammatory Bowel Diseases, Hospital of the University of Pennsylvania, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Curr Treat Options Gastroenterol 9:221-33. 2006
  8. ncbi request reprint Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 4:621-30. 2006
  9. ncbi request reprint Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Gastroenterology 128:862-9. 2005
  10. ncbi request reprint Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Gastroenterology 127:1558-64. 2004

Detail Information

Publications84

  1. pmc Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREATâ„¢ registry
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 107:1409-22. 2012
    ..The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD)...
  2. pmc A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Gastroenterol 107:1051-63. 2012
    ..The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and ulcerative colitis (UC) clinical trials...
  3. ncbi request reprint Review article: Bowel preparation for colonoscopy--the importance of adequate hydration
    G R Lichtenstein
    Hospital of the University of Pennsylvania, Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Aliment Pharmacol Ther 26:633-41. 2007
    ..Addressing dehydration-related safety issues through patient screening and education may improve acceptance of bowel preparations, promote compliance and increase the likelihood of a successful procedure...
  4. ncbi request reprint Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease
    Mark T Osterman
    Gary R Lichtenstein, MD Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Division of Gastroenterology, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Curr Treat Options Gastroenterol 10:195-207. 2007
    ..The future of anti-TNF therapy in inflammatory bowel disease is very bright, as exciting new developments continue to be made at a rapid pace...
  5. ncbi request reprint Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis
    Gary R Lichtenstein
    Center for Inflammatory Bowel Disease, University of Pennsylvania Health System, Philadelphia, PA, USA
    J Clin Gastroenterol 40:669-77. 2006
    ..Thus, despite the availability of ileal J-pouch-anal anastomosis, surgery does not always restore all aspects of QOL to normal...
  6. ncbi request reprint Prevention and treatment of osteoporosis in inflammatory bowel disease
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia, PA 19104 4283, USA
    Inflamm Bowel Dis 12:797-813. 2006
    ..They should not be interpreted as quality standards...
  7. ncbi request reprint Safety of biologics in inflammatory bowel disease
    Wojciech Blonski
    Center for Inflammatory Bowel Diseases, Hospital of the University of Pennsylvania, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Curr Treat Options Gastroenterol 9:221-33. 2006
    ..Moreover, postmarketing experience also provides very valuable information about any side effects occurring during treatment with this agent...
  8. ncbi request reprint Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 4:621-30. 2006
    ..Long-term safety data for infliximab and other therapies in Crohn's disease (CD) are needed...
  9. ncbi request reprint Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Gastroenterology 128:862-9. 2005
    ..We examined the effect of infliximab maintenance treatment on hospitalizations, surgeries, and procedures in patients with fistulizing Crohn's disease enrolled in the ACCENT II study...
  10. ncbi request reprint Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Gastroenterology 127:1558-64. 2004
  11. ncbi request reprint Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparation
    G R Lichtenstein
    University of Pennsylvania, Gastroenterology Division, Philadelphia, PA 19104 4283, USA
    Aliment Pharmacol Ther 26:1361-70. 2007
    ..Aim To compare patient acceptance, preference and tolerability of 32-sodium phosphate tablets vs. 2L polyethylene glycol solution plus 4 bisacodyl tablets for bowel preparation...
  12. doi request reprint Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis
    G R Lichtenstein
    Gastroenterology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Aliment Pharmacol Ther 29:643-53. 2009
    ..Aim To evaluate budesonide's safety profile in CD patients, in particular, incidences of clinically important AEs known to be associated with systemic GCSs...
  13. doi request reprint Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis
    G R Lichtenstein
    Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Aliment Pharmacol Ther 33:672-8. 2011
    ..Recent studies have focused on the importance of mucosal healing in ulcerative colitis (UC). However, it was still unclear whether higher doses of delayed-release mesalazine (mesalamine) could provide additional benefit...
  14. doi request reprint Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
    G R Lichtenstein
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Aliment Pharmacol Ther 30:210-26. 2009
    ..Benefits and risks of concomitant immunomodulators and maintenance infliximab in inflammatory bowel disease (IBD) patients have not been adequately evaluated...
  15. doi request reprint Bowel preparations for colonoscopy: a review
    Gary Lichtenstein
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Am J Health Syst Pharm 66:27-37. 2009
    ..The mechanisms of action, clinical efficacy, tolerability, and safety of two major classes of bowel purgatives, poly-ethylene glycol- electrolyte lavage solutions (PEG-ELSs) and sodium phosphate preparations, are reviewed...
  16. ncbi request reprint Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients
    Faten N Aberra
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Gastroenterology 125:320-7. 2003
    ....
  17. ncbi request reprint Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
    Gary R Lichtenstein
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 5:95-102. 2007
    ..We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis...
  18. ncbi request reprint Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis
    Mical S Campbell
    Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Liver Int 25:311-6. 2005
    ..Aim: To determine the association between the severity of liver disease and bone mineral density (BMD) in PSC patients...
  19. ncbi request reprint Infliximab in fistulizing Crohn's disease
    Mark T Osterman
    Division of Gastroenterology, Department of Medicine, Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine, 218 Wright Saunders Building, 39th and Market Streets, Philadelphia, PA 19104, USA
    Gastroenterol Clin North Am 35:795-820. 2006
    ..Proper fistula management also relies heavily on accurate diagnosis, especially defining the anatomy of the fistula, ascertaining whether abscess formation is present, and determining the location and extent of intestinal inflammation...
  20. ncbi request reprint Complications of biological therapy for inflammatory bowel diseases
    Wojciech Blonski
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Curr Opin Gastroenterol 22:30-43. 2006
    ..The purpose of this review is to analyze the complications associated with treatment of inflammatory bowel disease with biologic agents...
  21. ncbi request reprint Recent developments in inflammatory bowel disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Third Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Med Clin North Am 86:1497-523. 2002
    ....
  22. doi request reprint What is the optimal therapy for Crohn's disease: step-up or top-down?
    Ming Valerie Lin
    Department of Internal Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA
    Expert Rev Gastroenterol Hepatol 4:167-80. 2010
    ..Future clinical trials will be crucial in answering these questions...
  23. ncbi request reprint Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease
    John T Chang
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Nat Clin Pract Gastroenterol Hepatol 3:220-8. 2006
    ..This review provides insights into the use of antagonists of tumor-necrosis factor-alpha for the treatment of inflammatory bowel disease...
  24. doi request reprint Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates
    Mark T Osterman
    Division of Gastroenterology, Department of Medicine, Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Methods Find Exp Clin Pharmacol 31:41-6. 2009
    ..This review article summarizes the data on the use of both conventional aminosalicylates and MMX mesalamine in the treatment of ulcerative colitis...
  25. ncbi request reprint Infliximab in ulcerative colitis
    Faten N Aberra
    Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Gastroenterol Clin North Am 35:821-36. 2006
    ....
  26. ncbi request reprint Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 99:91-6. 2004
    ....
  27. ncbi request reprint Infliximab improves quality of life in patients with Crohn's disease
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Inflamm Bowel Dis 8:237-43. 2002
    ..The aim of this study was to assess the effect of infliximab on quality of life in patients with active Crohn's disease (CD) inadequately responsive to concomitant therapies...
  28. ncbi request reprint The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease
    Michael Pazianas
    Department of Medicine, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, PA 19104, USA
    Ann N Y Acad Sci 1068:543-56. 2006
    ....
  29. ncbi request reprint An evidence-based approach to studies of the natural history of gastrointestinal diseases: recurrence of symptomatic Crohn's disease after surgery
    James D Lewis
    Department of Medicine, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    Clin Gastroenterol Hepatol 1:229-36. 2003
  30. ncbi request reprint Seasonal variation in flares of inflammatory bowel disease
    James D Lewis
    Center for Clinical Epidemiology and Biostatistics and Department of Medicine, University of Pennsylvania Centers for Education and Research on Therapeutics, Philadelphia, 19104 6021, USA
    Gastroenterology 126:665-73. 2004
    ..The purpose of this study was to determine whether relapse of inflammatory bowel disease follows a seasonal pattern either across a cohort of patients or within individual patients...
  31. ncbi request reprint Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease
    Erick P Chan
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Gastroenterol Clin North Am 35:675-712. 2006
    ..Further studies, including prospective trials when possible and cost-effectiveness analyses, need to be performed to develop an optimal strategy for the reduction of cancer risk in patients with IBD...
  32. ncbi request reprint [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Rev Gastroenterol Mex 71:351-401. 2006
  33. ncbi request reprint A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania and University of Pennsylvania Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Gastroenterology 132:516-26. 2007
    ..The aims of this study were to estimate the placebo rates of remission and response in placebo-controlled, randomized clinical trials for active UC and to identify factors influencing these rates...
  34. ncbi request reprint Evaluation of bone mineral density in patients with inflammatory bowel disease
    Carmen Cuffari
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3rd Floor, Radvin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Curr Gastroenterol Rep 5:261-2. 2003
  35. doi request reprint A randomized, controlled, double-blind trial of patient-controlled sedation with propofol/remifentanil versus midazolam/fentanyl for colonoscopy
    Jeff E Mandel
    Department of Anesthesiology and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Anesth Analg 106:434-9, table of contents. 2008
    ..We hypothesized that, by using remifentanil in conjunction with propofol and using PCS in both arms of the study, we could demonstrate marked improvements in facility use compared with fentanyl plus midazolam...
  36. pmc Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial
    James D Lewis
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Gastroenterology 134:688-95. 2008
    ..Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC)...
  37. pmc Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
    James D Lewis
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    Inflamm Bowel Dis 14:1660-6. 2008
    ..We sought to assess what constitutes a clinically meaningful change in these indices using data from a recently completed placebo-controlled clinical trial...
  38. doi request reprint Management of Crohn's disease in adults
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 104:465-83; quiz 464, 484. 2009
    ..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time...
  39. ncbi request reprint Treatment of fistulizing Crohn's disease
    Thomas A Judge
    Gastroenterology Division, Robert Wood Johnson Medical School, Cooper University Hospital, University of Medicine and Dentistry of New Jersey, 401 Hadden Avenue, Room 374, Camden, NJ 08103, USA
    Gastroenterol Clin North Am 33:421-54, xi-xii. 2004
    ..The appropriate approach to asymptomatic patients is uncertain because there are little data to indicate if treatment alters the natural course of disease...
  40. doi request reprint Importance of mucosal healing in ulcerative colitis
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Inflamm Bowel Dis 16:338-46. 2010
    ..This review evaluates the effect of medical therapy on mucosal healing in patients with UC and explores the importance of this outcome measure, both from the patient's perspective and clinical trial experience. Inflamm Bowel Dis 2009...
  41. pmc Efficacy and safety of adalimumab in Crohn's disease
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine Hospital of the University of Pennsylvania, 3rd Floor Ravdin Building 3400 Spruce Street Philadelphia, PA, USA
    Therap Adv Gastroenterol 1:43-50. 2008
    ..Based on robust short- and long-term efficacy data from large randomized controlled trials and a favorable safety signal, ADA has become a key addition to the therapeutic armamentarium in the treatment of moderate-to-severe CD...
  42. ncbi request reprint A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, UPenn Medical Center Presbyterian, 218 Wright Saunders Building, 39th and Market Streets, Philadelphia, PA 19104, USA
    Gastroenterology 126:1257-69. 2004
    ..The aims of this study were to estimate rates of remission and response in patients with active CD receiving placebo and to identify factors influencing these rates...
  43. ncbi request reprint Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Gastroenterol Clin North Am 33:209-34, viii. 2004
    ..Emerging literature on the potential application of pharmacogenetic testing and metabolite monitoring are also discussed...
  44. ncbi request reprint Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy
    Gary R Lichtenstein
    Department of Medicine, Hospital of the University of Pennsylvania, School of Medicine, PA, USA
    Am J Gastroenterol 100:1433-5. 2005
  45. ncbi request reprint Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Inflamm Bowel Dis 10:S2-10. 2004
    ..Here we also evaluate the current preferable treatment practices, based on scientifically valid research and collective clinical experience, for the management of mild to moderate Crohn's disease...
  46. ncbi request reprint Antibiotic use and the risk of flare of inflammatory bowel disease
    Faten N Aberra
    Division of Gastroenterolgy, University of Pennsylvania School of Medicine, Philadephia, 19104, USA
    Clin Gastroenterol Hepatol 3:459-65. 2005
    ..Intestinal microbial flora participate in the pathogenesis of inflammatory bowel disease. Because antibiotic therapy alters intestinal microbial flora, we hypothesized that use of antibiotics might decrease the risk of flare...
  47. doi request reprint Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months
    Gary R Lichtenstein
    Gastrointestinal Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 8:600-9. 2010
    ..We assessed the long-term efficacy, safety, and immunogenicity of continuous versus interrupted maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease...
  48. ncbi request reprint Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Inflamm Bowel Dis 10:S11-21. 2004
  49. ncbi request reprint Infliximab use in Crohn's disease
    Meenakshi Bewtra
    University of Pennsylvania Health System, 100 Centrex, IMR, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Expert Opin Biol Ther 5:589-99. 2005
    ..The clinical efficacy, indications, safety profile and future of infliximab are reviewed...
  50. ncbi request reprint Methods to avoid infections in patients with inflammatory bowel disease
    Faten N Aberra
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Inflamm Bowel Dis 11:685-95. 2005
    ..Recommendations are also provided for prevention of infection...
  51. ncbi request reprint Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Dig Dis Sci 53:175-80. 2008
    ..22). No severe adverse events were observed. This trial suggests a potential benefit over placebo for both achieving clinical response and induction of remission in patients with active ulcerative colitis without apparent toxicity...
  52. ncbi request reprint Risk for active tuberculosis in inflammatory bowel disease patients
    Faten N Aberra
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 5:1070-5. 2007
    ..The primary aim of this study was to determine the incidence of active tuberculosis in an inflammatory bowel disease population compared with the general population before the availability of infliximab...
  53. ncbi request reprint Evaluation of polypoid lesions in inflammatory bowel disease
    Ashish Chawla
    Center for Inflammatory Bowel Disease, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Department of Medicine, Division of Gastroenterology, 3400 Spruce Street, Ravdin Building, Philadelphia, PA 19104 4283, USA
    Gastrointest Endosc Clin N Am 12:525-34, ix. 2002
    ..The patients who have indeterminate lesions can be differentiated based on the endoscopic, histologic, and molecular features of the lesion. Long-term follow-up is necessary to determine the natural history of these lesions...
  54. ncbi request reprint Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Rev Gastroenterol Disord 8:21-30; quiz 31-2. 2008
    ..Novel formulations of mesalamine and newly devised, high-dose regimens offer additional therapeutic options and may lead to improved treatment adherence, longer-lasting periods of remission, and enhanced patient well-being...
  55. ncbi request reprint Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 101:1030-8. 2006
    ..Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs)...
  56. ncbi request reprint Evaluation of bone mineral density in inflammatory bowel disease: current safety focus
    Gary R Lichtenstein
    Center for Inflammatory Bowel Diseases, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Am J Gastroenterol 98:S24-30. 2003
    ..This review discusses the pathophysiology involved in the formation of abnormal bone mineral density and the treatment of this condition in patients with inflammatory bowel disease...
  57. ncbi request reprint Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis
    Jeffry A Katz
    Division of Gastroenterology, Case Western Reserve University, Cleveland, Ohio 44106 5066, USA
    Am J Gastroenterol 99:2385-92. 2004
    ..Infliximab is approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). We report the first large series of pregnancy outcomes in women with RA and CD exposed to infliximab...
  58. ncbi request reprint The impact of increased body mass index on the clinical course of Crohn's disease
    David J Hass
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 4:482-8. 2006
    ..This study evaluated overweight patients with CD to determine if their clinical course differs from those with a normal or low body mass index (BMI)...
  59. ncbi request reprint Crohn's disease in the ileal pouch after total colectomy for ulcerative colitis: findings on pouch enemas in six patients
    Nicolaus A Wagner-Bartak
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA
    AJR Am J Roentgenol 184:1843-7. 2005
    ....
  60. ncbi request reprint Reduction of colorectal cancer risk in patients with Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Rev Gastroenterol Disord 2:S16-24. 2002
    ..This article reviews the current literature relating to the risk of cancer for patients with IBD and methods available to help reduce this risk...
  61. doi request reprint A prospective, randomized, comparative trial evaluating respiratory depression during patient-controlled versus anesthesiologist-administered propofol-remifentanil sedation for elective colonoscopy
    Jeff E Mandel
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Gastrointest Endosc 72:112-7. 2010
    ..Patient-controlled sedation (PCS) with propofol-remifentanil (PR) is associated with rapid sedation and recovery, but it is associated with a greater requirement for airway rescue than PCS with midazolam-fentanyl...
  62. ncbi request reprint Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
    Chinyu Su
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Am J Gastroenterol 97:2577-84. 2002
    ..Preclinical studies suggest the importance of TNF-alpha in treating ulcerative colitis (UC). We report the effectiveness of infliximab for UC and examine factors predictive of response to medication...
  63. ncbi request reprint Are there predictors of Remicade treatment success or failure?
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Adv Drug Deliv Rev 57:237-45. 2005
    ..Data from the literature in these areas are reviewed in this article, pointing to the need for additional research in this topic...
  64. doi request reprint High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitis
    Wojciech Blonski
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, USA
    Scand J Gastroenterol 43:817-20. 2008
    ..We hypothesize that colectomy is not warranted in patients who undergo complete excision of adenoma-like DALMs with HGD in UC...
  65. ncbi request reprint Corticosteroids in Crohn's disease
    Yu Xiao Yang
    Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Am J Gastroenterol 97:803-23. 2002
    ..Alternative classes of medical therapy for Crohn's disease, including modified corticosteroids and a group of new biological therapies, have proven to be efficacious in the management of active and/or quiescent Crohn's disease...
  66. ncbi request reprint Medical therapy of inflammatory bowel disease
    Gary R Lichtenstein
    Gastroenterology Division, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, University of Pennsylvania Health System, Philadelphia, PA 19104 4283, USA
    Gastroenterol Clin North Am 33:xv-xvi. 2004
  67. ncbi request reprint Colonic dysplasia and cancer in inflammatory bowel disease
    Thomas A Judge
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor Ravdin Building, Philadelphia, PA 19104 4283, USA
    Gastrointest Endosc Clin N Am 12:495-523. 2002
    ..Efforts to develop chemopreventative agents and improved surveillance methods remain areas of active investigation...
  68. doi request reprint Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?
    Wojciech Blonski
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Scand J Gastroenterol 43:698-703. 2008
    ..The aim of this study was to determine whether dysplasia is visible during routine surveillance colonoscopy by evaluating only patients who had dysplasia without overt carcinoma...
  69. ncbi request reprint Recent developments in the pharmacological treatment of Crohn's disease
    Radhika Srinivasan
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    Expert Opin Investig Drugs 13:373-91. 2004
    ..The future for CD patients is promising with the ever-expanding repertoire of drugs that are being studied...
  70. ncbi request reprint Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis
    Mark T Osterman
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Gastroenterology 130:1047-53. 2006
    ..Previous studies, most with small sample sizes, yielded conflicting conclusions. Our aim was to pool the available data to provide a more precise estimate of the association between 6-TGN levels and IBD activity...
  71. ncbi request reprint An approach to the management of refractory ulcerative colitis
    I Sonu
    University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
    Minerva Gastroenterol Dietol 56:213-31. 2010
    ..This review focuses on the management and treatment approaches to refractory UC...
  72. ncbi request reprint American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA
    Gastroenterology 130:940-87. 2006
  73. ncbi request reprint American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA
    Gastroenterology 130:935-9. 2006
  74. ncbi request reprint Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the question
    Wojciech Blonski
    Gastrointest Endosc 63:493-6. 2006
  75. ncbi request reprint Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastrointest Endosc 63:433-42; quiz 464. 2006
    ....
  76. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 353:2462-76. 2005
    ..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis...
  77. ncbi request reprint What next after infliximab?
    Leonard Baidoo
    Am J Gastroenterol 100:80-3. 2005
    ..Is this a viable alternative?..
  78. ncbi request reprint Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastroenterology 126:402-13. 2004
    ..This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice...
  79. ncbi request reprint Safety of biologic therapy
    Wojciech Blonski
    Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland
    Inflamm Bowel Dis 13:769-96. 2007
    ..This is because it has been evaluated in many more trials than has any other biologic agent. In addition, postmarketing experience provides very valuable information about adverse events occurring during treatment with this agent...
  80. ncbi request reprint An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial
    Douglas L Seidner
    Department of Gastroenterology A30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Gastroenterol Hepatol 3:358-69. 2005
    ....
  81. ncbi request reprint The effects of infliximab maintenance therapy on health-related quality of life
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
    Am J Gastroenterol 98:2232-8. 2003
    ..The ACCENT I study evaluated the long term effects of infliximab as maintenance therapy for patients with Crohn's disease. Health-related quality of life (HRQL) was also assessed in the trial...
  82. ncbi request reprint Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
    Carmen Cuffari
    Gastroenterology 124:1988-90. 2003
  83. ncbi request reprint Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update
    David T Rubin
    University of Chicago Medical Center, Chicago, IL 60637, USA
    Inflamm Bowel Dis 14:265-74. 2008
    ..This article provides a comprehensive overview of the issues discussed and should act as a guide to shaping the design of future studies in this area...
  84. ncbi request reprint Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
    ..We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab...